Can CK-MB be used as a marker in benign paroxysmal positional vertigo attack?

ABSTRACT

OBJECTIVES: Benign paroxysmal positional vertigo (BPPV) is one of the main causes of vertigo. More than 90% of cases of positional vertigo and nystagmus can be associated with BPPV. There is no known specific laboratory test for BPPV. Because of the possible muscle activity in BPPV (especially result of nause, vomiting and increasing heart rate) we thought the CK-MB levels may change in this situation. The purpose of this study was to investigate the relation between serum CK-MB levels and BPPV and attacks. MATERIALS AND METHODS: The medical records of 35 patients with BPPV presenting to our clinic between November 2014 and November 2015 were investigated retrospectively. Thirty-two control patients with no vertigo, muscular or cardiac disease and with measured CK-MB levels were randomized into a control group. Both groups' existing CK-MB levels were obtained from the patient records. CK-MB values measured before BPPV attack from 11 patients in the patient group were also recorded. RESULTS: The patient and control groups were similar in terms of demographic parameters. CK-MB values at time of attack in the patient group ranged between 5.4 and 38.9 (mean 19.67 ± 6.81), while control group values ranged between 12 and 27.9 (mean 20.31 ± 4.54). CK-MB values in 11 patients in the patient group measured before attack ranged between 8.9 and 24 (mean 17.02 ± 4.97), and CK-MB values during attack ranged between 9 and 34 (mean 19.74 ± 7.64). CONCLUSION: Although CK-MB elevation at time of attack was determined in patients with BPPV, this was not statistically significant.